Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10137354 | 0.81 | PCSK9 (0.41) | HRH3 | |
| SCHEMBL794275 | 0.80 | ALDH1A1 (0.49) | AKR1C3ALDH1A1KDM4EKMT2ANPC1 | |
| SCHEMBL22554161 | 0.77 | PDGFRB (0.43) | AKR1C3ALDH1A1KDM4EKMT2AHRH3 | |
| SCHEMBL20315309 | 0.77 | PARP1 (0.41) | ALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL2700073 | 0.76 | ALDH1A1 (0.44) | AKR1C3ALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL17841510 | 0.74 | CCR6 (0.41) | ALDH1A1KDM4EKMT2ANPC1HPGD | |
| SCHEMBL10258354 | 0.74 | CNR2 (0.44) | HRH3 | |
| SCHEMBL12068158 | 0.74 | KMT2A (0.52) | ALDH1A1KDM4EKMT2ASMN1; SMN2HPGD | |
| SCHEMBL29734988 | 0.74 | ALDH1A1 (0.46) | AKR1C3ALDH1A1KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL26921780 | 0.74 | ALDH1A1 (0.46) | AKR1C3ALDH1A1KDM4EKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181235-B2 | Substituted pyridines for modulating the WNT signaling pathway | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9181235-B2 | Substituted pyridines for modulating the WNT signaling pathway | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2013-03-28 | — | — | US | disclosed |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | WNT3A, WNT1, WNT3 | AKR1C3 788/4885ALDH1A1 3196/4885KDM4E 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.